Skip to main content

Table 1 Associations between p-p70S6K and clinico-pathological variables as well as other PI3K and/or MAPK pathway proteins

From: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

 

p-p70S6K (n = 438)

 
 

Negative (n = 188)

Positive (n = 250)

P value

Treatment

No tamoxifen

40 (21)

55 (22)

0.92a

Tamoxifen 1 year

89 (47)

113 (45)

Tamoxifen 3 years

59 (31)

82 (33)

Age

<65

82 (44)

128 (51)

0.12b

≥65

106 (56)

122 (49)

Lymph node

Negative

92 (49)

141 (56)

0.12b

Positive

96 (51)

109 (44)

T stage

T1 to T2

167 (89)

221 (88)

1.00b

T3 to T4

21 (11)

29 (12)

Grade

Grade 1 to 2

123 (65)

153 (61)

0.37b

Grade 3

65 (35)

97 (39)

Progesterone receptor

Negative

98 (52)

111 (44)

0.10b

Positive

88 (47)

139 (56)

Missing

2 (1)

0 (0)

HER2

Negative

168 (89)

223 (89)

0.17b

Positive

12 (6)

26 (10)

Missing

8 (4)

1 (0)

p-AKT(Ser473)c

Low (0 to 1)

109 (71)

53 (24)

<0.0001b

High (2 to 3)

44 (29)

172 (76)

p-AKT(Thr308)c

Negative

143 (81)

87 (36)

<0.0001b

Positive

34 (20)

153 (64)

p-mTORc

Low (0 to 59%)

156 (87)

176 (73)

0.0003b

High (≥60%)

23 (13)

66 (27)

p-ERK1/2c

Negative

114 (65)

61 (26)

<0.0001b

 

Positive

61 (35)

177 (74)

 
  1. Data presented as n (%). ERK, extracellular signal-regulated kinase; HER2, human epidermal growth factor receptor 2; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase; p, phosphorylated. aLinear by linear test. bFisher’s exact test (analysis based on cases without missing values). cMissing data not shown.